FAQ Module: Special Populations and Comorbidities
Frequently Asked Questions on COVID-19 in Special Populations and Patients With Comorbidities

Released: July 08, 2020

Expiration: July 07, 2021

Vikramjit Mukherjee
Vikramjit Mukherjee, MD
Lynora Saxinger
Lynora Saxinger, MD, FRCPC, CTropMed

Activity

Progress
1
Course Completed

References

Alqahatani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity, and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15:e0233147.

Blanco J, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314-e316.

Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 Patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14:813-821.

Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020;Epub ahead of print.

British HIV Association. BHIVA interim ART guidelines COVID-19 v2 07082020. Available at: https://www.bhiva.org/file/5f56057450cc3/BHIVA-interim-ART-guidelines-COVID-19.pdf. Accessed November 13, 2020.

ClinicalTrials.gov. Randomized clinical trial for the prevention of SARS-CoV-2 infection (COVID-19) in healthcare personnel (EPICOS). Available at: https://clinicaltrials.gov/ct2/show/NCT04334928. Accessed November 13, 2020.

ClinicalTrials.gov. The coronavirus disease 2019 angiotensin converting enzyme inhibitor/angiotensin receptor blocker investigation (CORONACION) randomized clinical trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04330300. Accessed November 13, 2020.

del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. 2020;Jun 26:M20-3689.

Elfiky A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592.

Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648-654.

Mirzaei J, MeFarland W, Karamouzian M, et al. COVID-19 among people living with HIV: a systematic review. AIDS Behav. 2020:1-8.

Park LS. COVID-19 in the largest US HIV cohort. Program and abstracts of the 23rd International AIDS Conference Virtual (AIDS 2020); July 6-10, 2020. Abstract LBPEC23.

Qui H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20:689-696.

Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes. Diabet Med. 2020:e14378.

Sigel K, Swartz T, Golden E, et al. Covid-19 and people with HIV infection: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;Epub ahead of print.

Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11:3774.

Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.

Zrzavy T, Wimmer I, Rommer PS, et al. Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol. 2020;Epub ahead of print.